• Home
  • CONTINUUS PHARMACEUTICALS

CONTINUUS PHARMACEUTICALS

About CONTINUUS PHARMACEUTICALS

CONTINUUS Pharmaceuticals is a spin-out company from a multi-year collaboration between MIT and Novartis. We specialize in end-to-end Integrated Continuous Manufacturing (ICM), with the application of novel process technologies that enable the rapid production of pharmaceuticals at significantly reduced costs and better quality assurance. With ICM, we will improve affordability and accessibility o...

Read more Show less
Sales Markets
Show more Show less
Categories
more categories Show less
  • Country/Region:
    United States
  • On CPHI since:
    2023
  • Employees:
    50 - 99
Company types
CMO/CDMO
Contract Research Organisation (CRO)
Engineering
Pharmaceutical company
Contact info
  • +1-8579997728
  • 25R Olympia Ave, 01801, Woburn, Massachusetts, United States
Show contact info Hide contact info

Products from CONTINUUS PHARMACEUTICALS (3)

  • Continuous Drug Product

    Product Continuous Drug Product

    Our proprietary Integrated Extrusion-Molding process produces pharmaceutical-grade coated tablets in a continuous fashion. The drug substance is conveyed from the upstream continuous dryer to the loss-in-weight feeder dedicated to the API, which is placed above the twin-screw extruder of the EM unit and in...
  • Dryer

    Product Dryer

    Continuous Drum Dryer: Our novel continuous dryer converts concentrated or diluted suspensions containing the API into a dry, flowable powder in just a few minutes. The suspension is deposited onto two heated rotating drums, forming thin layers that are quickly dried. The entire system is under vacuum, all...
  • End-to-end continuous manufacturing

    Product End-to-end continuous manufacturing

    Our technology and expertise enable seamless end-to-end continuous manufacturing processes that incorporate API formation steps with final drug product formulation. More specifically, by eliminating all the stops-and-starts that make current manufacturing processes time- and cost-inefficient, we are able t...